{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:10:53Z","timestamp":1791868253917,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"AstraZeneca K.K."},{"DOI":"10.13039\/501100009035","name":"Program on Open Innovation Platform with Enterprises, Research Institute and Academia","doi-asserted-by":"publisher","award":["JPMJOP1842"],"award-info":[{"award-number":["JPMJOP1842"]}],"id":[{"id":"10.13039\/501100009035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004721","name":"The University of Tokyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004721","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s12325-025-03157-z","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T08:09:55Z","timestamp":1745914195000},"page":"2888-2905","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost-Effectiveness Analysis of SGLT2 Inhibitors for Cardio-Renal-Metabolic Disease Based on Data from Japanese Studies"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6307-6916","authenticated-orcid":false,"given":"Ataru","family":"Igarashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisateru","family":"Tachimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Maruyama-Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasumasa","family":"Segawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiko","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Kohsaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"3157_CR1","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1111\/dom.14829","volume":"24","author":"T Kadowaki","year":"2022","unstructured":"Kadowaki T, Maegawa H, Watada H, et al. Interconnection between cardiovascular, renal and metabolic disorders: a narrative review with a focus on Japan. Diabetes Obes Metab. 2022;24:2283\u201396.","journal-title":"Diabetes Obes Metab"},{"key":"3157_CR2","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/dom.14074","volume":"22","author":"KI Birkeland","year":"2020","unstructured":"Birkeland KI, Bodegard J, Eriksson JW, et al. Heart failure and chronic kidney disease manifestation and mortality risk associations in type\u00a02 diabetes: a large multinational cohort study. Diabetes Obes Metab. 2020;22:1607\u201318.","journal-title":"Diabetes Obes Metab"},{"key":"3157_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s13300-021-01191-y","volume":"13","author":"T Kadowaki","year":"2022","unstructured":"Kadowaki T, Komuro I, Morita N, Akiyama H, Kidani Y, Yajima T. Manifestation of heart failure and chronic kidney disease are associated with increased mortality risk in early stages of type\u00a02 diabetes mellitus: analysis of a Japanese real-world hospital claims database. Diabetes Ther. 2022;13:275\u201386.","journal-title":"Diabetes Ther"},{"key":"3157_CR4","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","volume":"139","author":"J Rangaswami","year":"2019","unstructured":"Rangaswami J, Bhalla V, Blair JEA, et al. American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology. Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019;139:e840\u201378.","journal-title":"Circulation"},{"key":"3157_CR5","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","volume":"143","author":"J Jankowski","year":"2021","unstructured":"Jankowski J, Floege J, Fliser D, B\u00f6hm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143:1157\u201372.","journal-title":"Circulation"},{"key":"3157_CR6","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ejhf.778","volume":"19","author":"M Nayor","year":"2017","unstructured":"Nayor M, Larson MG, Wang N, et al. The association of chronic kidney disease and microalbuminuria with heart failure with preserved vs reduced ejection fraction. Eur J Heart Fail. 2017;19:615\u201323.","journal-title":"Eur J Heart Fail"},{"key":"3157_CR7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40273-020-00984-6","volume":"39","author":"GL Di Tanna","year":"2021","unstructured":"Di Tanna GL, Urbich M, Wirtz HS, et al. Health state utilities of patients with heart failure: a systematic literature review. Pharmacoeconomics. 2021;39:211\u201329.","journal-title":"Pharmacoeconomics"},{"key":"3157_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s41100-021-00382-4","volume":"7","author":"S Noto","year":"2021","unstructured":"Noto S, Miyazaki M, Takeuchi H, Saito S. Relationship between hemodialysis and health-related quality of life: a cross-sectional study of diagnosis and duration of hemodialysis. Ren Replace Ther. 2021;7:62.","journal-title":"Ren Replace Ther"},{"key":"3157_CR9","doi-asserted-by":"publisher","first-page":"416","DOI":"10.34067\/KID.0000162020","volume":"1","author":"N Hanafusa","year":"2020","unstructured":"Hanafusa N, Fukagawa M. Global dialysis perspective: Japan. Kidney360. 2020;1:416\u20139.","journal-title":"Kidney360"},{"key":"3157_CR10","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1253\/circj.CJ-18-1212","volume":"83","author":"K Kanaoka","year":"2019","unstructured":"Kanaoka K, Okayama S, Nakai M, et al. Hospitalization costs for patients with acute congestive heart failure in Japan. Circ J. 2019;83:1025\u201331.","journal-title":"Circ J"},{"key":"3157_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. DECLARE\u2013TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med."},{"key":"3157_CR12","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008.","journal-title":"N Engl J Med"},{"key":"3157_CR13","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"3157_CR14","doi-asserted-by":"publisher","first-page":"1111984","DOI":"10.3389\/fendo.2023.1111984","volume":"14","author":"H Akiyama","year":"2023","unstructured":"Akiyama H, Nishimura A, Morita N, Yajima T. Evolution of sodium-glucose co-transporter\u00a02 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome. Front Endocrinol (Lausanne). 2023;14:1111984.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3157_CR15","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1016\/j.clinthera.2019.07.016","volume":"41","author":"K Kaku","year":"2019","unstructured":"Kaku K, Haneda M, Sakamaki H, et al. Cost-effectiveness analysis of empagliflozin in Japan based on results from the Asian subpopulation in the EMPA-REG OUTCOME trial. Clin Ther. 2019;41:2021\u201340.e11.","journal-title":"Clin Ther"},{"key":"3157_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.750381","volume":"8","author":"CT Liao","year":"2021","unstructured":"Liao CT, Yang CT, Kuo FH, et al. Cost-effectiveness evaluation of add-on empagliflozin in patients with heart failure and a reduced ejection fraction from the healthcare system\u2019s perspective in the Asia-Pacific region. Front Cardiovasc Med. 2021;8:750381.","journal-title":"Front Cardiovasc Med"},{"key":"3157_CR17","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1253\/circj.CJ-22-0086","volume":"86","author":"S Kodera","year":"2022","unstructured":"Kodera S, Morita H, Nishi H, Takeda N, Ando J, Komuro I. Cost-effectiveness of dapagliflozin for chronic kidney disease in Japan. Circ J. 2022;86:2021\u20138.","journal-title":"Circ J"},{"key":"3157_CR18","doi-asserted-by":"publisher","first-page":"sfae025","DOI":"10.1093\/ckj\/sfae025","volume":"17","author":"P McEwan","year":"2024","unstructured":"McEwan P, Davis JA, Gabb PD, et al. Dapagliflozin in chronic kidney disease: Cost-effectiveness beyond the DAPA-CKD trial. Clin Kidney J. 2024;17:sfae025.","journal-title":"Clin Kidney J"},{"key":"3157_CR19","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1111\/dom.15832","volume":"26","author":"K Maruyama-Sakurai","year":"2024","unstructured":"Maruyama-Sakurai K, Tachimori H, Saito E, et al. Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in the treatment of diabetic nephropathy in Japan. Diabetes Obes Metab. 2024;26:5546\u201355.","journal-title":"Diabetes Obes Metab"},{"key":"3157_CR20","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1111\/jdi.13485","volume":"12","author":"S Kohsaka","year":"2021","unstructured":"Kohsaka S, Kumamaru H, Nishimura S, et al. Incidence of adverse cardiovascular events in type\u00a02 diabetes mellitus patients after initiation of glucose-lowering agents: a population-based community study from the Shizuoka Kokuho database. J Diabetes Investig. 2021;12:1452\u201361.","journal-title":"J Diabetes Investig"},{"key":"3157_CR21","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/ndt\/gfac040","volume":"37","author":"EMPA-KIDNEY Collaborative Group","year":"2022","unstructured":"EMPA-KIDNEY Collaborative Group. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol Dial Transplant. 2022;37:1317\u201329.","journal-title":"Nephrol Dial Transplant"},{"key":"3157_CR22","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/MLR.0000000000001301","volume":"58","author":"S Fukuma","year":"2020","unstructured":"Fukuma S, Ikenoue T, Shimizu S, et al. and on behalf of BiDANE: Big Data Analysis of Medical Care for the Older in Kyoto. Quality of care in chronic kidney disease and incidence of end-stage renal disease in older patients: A cohort study. Med Care. 2020;58:625\u201331.","journal-title":"Med Care"},{"key":"3157_CR23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s10157-021-02136-2","volume":"26","author":"M Iwase","year":"2022","unstructured":"Iwase M, Ide H, Ohkuma T, et al. Incidence of end-stage renal disease and risk factors for progression of renal dysfunction in Japanese patients with type\u00a02 diabetes: the Fukuoka Diabetes Registry. Clin Exp Nephrol. 2022;26:122\u201331.","journal-title":"Clin Exp Nephrol"},{"key":"3157_CR24","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1253\/circj.CJ-12-0982","volume":"77","author":"M Ohsawa","year":"2013","unstructured":"Ohsawa M, Tanno K, Itai K, et al. Comparison of predictability of future cardiovascular events between chronic kidney disease (CKD) stage based on CKD epidemiology collaboration equation and that based on modification of diet in renal disease equation in the Japanese general population\u2013Iwate KENCO Study. Circ J. 2013;77:1315\u201325.","journal-title":"Circ J"},{"key":"3157_CR25","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1681\/ASN.2006101159","volume":"18","author":"A Kottgen","year":"2007","unstructured":"Kottgen A, Russell SD, Loehr LR, et al. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol. 2007;18:1307\u201315.","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 2","key":"3157_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/dom.14119","volume":"23","author":"I Komuro","year":"2021","unstructured":"Komuro I, Kadowaki T, Bodeg\u00e5rd J, Thuresson M, Okami S, Yajima T. Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type\u00a02 diabetes patients without established cardiovascular and renal diseases. Diabetes Obes Metab. 2021;23(Suppl 2):19\u201327.","journal-title":"Diabetes Obes Metab"},{"key":"3157_CR27","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","volume":"140","author":"KW Mahaffey","year":"2019","unstructured":"Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and cardiovascular and renal outcomes in type\u00a02 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation. 2019;140:739\u201350.","journal-title":"Circulation"},{"key":"3157_CR28","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2020.1906","volume":"323","author":"MC Petrie","year":"2020","unstructured":"Petrie MC, Verma S, Docherty KF, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323:1353\u201368.","journal-title":"JAMA"},{"key":"3157_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","volume":"9","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Stef\u00e1nsson BV, Jongs N, et al. DAPA-CKD Trial Committees and Investigators. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9:22\u201331.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3157_CR30","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.120.051675","volume":"143","author":"JJV McMurray","year":"2021","unstructured":"McMurray JJV, Wheeler DC, Stef\u00e1nsson BV, et al. DAPA-CKD Trial Committees and Investigators. Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease. Circulation. 2021;143:438\u201348.","journal-title":"Circulation"},{"key":"3157_CR31","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1007\/s13300-020-00938-3","volume":"11","author":"H Ishii","year":"2020","unstructured":"Ishii H, Takamura H, Nishioka Y, et al. Quality of life and utility values for cost-effectiveness modeling in Japanese patients with type\u00a02 diabetes. Diabetes Ther. 2020;11:2931\u201343.","journal-title":"Diabetes Ther"},{"key":"3157_CR32","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1007\/s13300-022-01270-8","volume":"13","author":"A Igarashi","year":"2022","unstructured":"Igarashi A, Maruyama-Sakurai K, Kubota A, et al. Cost-effectiveness analysis of initiating type\u00a02 diabetes therapy with a sodium-glucose cotransporter\u00a02 inhibitor versus conventional therapy in Japan. Diabetes Ther. 2022;13:1367\u201381.","journal-title":"Diabetes Ther"},{"key":"3157_CR33","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s10157-010-0304-1","volume":"14","author":"R Tajima","year":"2010","unstructured":"Tajima R, Kondo M, Kai H, et al. Measurement of health-related quality of life in patients with chronic kidney disease in Japan with EuroQol (EQ-5D). Clin Exp Nephrol. 2010;14:340\u20138.","journal-title":"Clin Exp Nephrol"},{"key":"3157_CR34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12955-020-01407-y","volume":"18","author":"MB Betts","year":"2020","unstructured":"Betts MB, Rane P, Bergrath E, et al. Utility value estimates in cardiovascular disease and the effect of changing elicitation methods: a systematic literature review. Health Qual Life Outcomes. 2020;18:251.","journal-title":"Health Qual Life Outcomes"},{"key":"3157_CR35","first-page":"31","volume":"8","author":"R Izumi","year":"2021","unstructured":"Izumi R, Noto S, Sano T, Suzuki T. Changes in health-related quality of life and concordance of proxy responses in convalescent rehabilitation wards: assessment of stroke patients using the EQ-5D-5L. Nihon Rinsho Sagyo Ryoho Kenkyu [Jpn J Clin Occupat Ther]. 2021;8:31\u20136 (in Japanese).","journal-title":"Nihon Rinsho Sagyo Ryoho Kenkyu [Jpn J Clin Occupat Ther]"},{"key":"3157_CR36","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12955-020-01483-0","volume":"18","author":"E Watanabe-Fujinuma","year":"2020","unstructured":"Watanabe-Fujinuma E, Origasa H, Bamber L, et al. Psychometric properties of the Japanese version of the Kansas City Cardiomyopathy Questionnaire in Japanese patients with chronic heart failure. Health Qual Life Outcomes. 2020;18:236.","journal-title":"Health Qual Life Outcomes"},{"key":"3157_CR37","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s13300-019-0597-3","volume":"10","author":"B Sinha","year":"2019","unstructured":"Sinha B, Ghosal S. Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduce hospitalization for heart failure only and have no effect on atherosclerotic cardiovascular events: a meta-analysis. Diabetes Ther. 2019;10:891\u20139.","journal-title":"Diabetes Ther"},{"key":"3157_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ahj.2020.10.064","volume":"232","author":"HM Salah","year":"2021","unstructured":"Salah HM, Al\u2019Aref SJ, Khan MS, et al. Effect of sodium-glucose cotransporter\u00a02 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials. Am Heart J. 2021;232:10\u201322.","journal-title":"Am Heart J"},{"key":"3157_CR39","doi-asserted-by":"publisher","DOI":"10.2196\/16053","volume":"22","author":"S Tsuji","year":"2020","unstructured":"Tsuji S, Ishikawa T, Morii Y, et al. Cost-effectiveness of a continuous glucose monitoring mobile app for patients with type\u00a02 diabetes mellitus: analysis simulation. J Med Internet Res. 2020;22:e16053.","journal-title":"J Med Internet Res"},{"key":"3157_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-067386","volume":"13","author":"N Tangri","year":"2023","unstructured":"Tangri N, Moriyama T, Schneider MP, et al. Prevalence of undiagnosed stage\u00a03 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study. BMJ Open. 2023;13:e067386.","journal-title":"BMJ Open"},{"key":"3157_CR41","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1038\/s41598-024-55827-7","volume":"14","author":"T Tanaka","year":"2024","unstructured":"Tanaka T, Maruyama S, Chishima N, et al. Population characteristics and diagnosis rate of chronic kidney disease by eGFR and proteinuria in Japanese clinical practice: an observational database study. Sci Rep. 2024;14:5172.","journal-title":"Sci Rep"},{"key":"3157_CR42","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1111\/dom.14162","volume":"22","author":"P McEwan","year":"2020","unstructured":"McEwan P, Bennett H, Khunti K, et al. Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type\u00a02 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence. Diabetes Obes Metab. 2020;22:2364\u201374.","journal-title":"Diabetes Obes Metab"},{"key":"3157_CR43","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.14501","volume":"4","author":"N Isaza","year":"2021","unstructured":"Isaza N, Calvachi P, Raber I, et al. Cost-effectiveness of dapagliflozin for the treatment of heart failure with reduced ejection fraction. JAMA Netw Open. 2021;4:e2114501.","journal-title":"JAMA Netw Open"},{"key":"3157_CR44","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.2215\/CJN.03790322","volume":"17","author":"P McEwan","year":"2022","unstructured":"McEwan P, Darlington O, Miller R, et al. Cost-effectiveness of dapagliflozin as a treatment for chronic kidney disease: a health-economic analysis of DAPA-CKD. Clin J Am Soc Nephrol. 2022;17:1730\u201341.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3157_CR45","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, et al. ESC Scientific Document Group. Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44:3627\u201339.","journal-title":"Eur Heart J"},{"key":"3157_CR46","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, et al. ESC Scientific Document Group. ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44:4043\u2013140.","journal-title":"Eur Heart J"},{"key":"3157_CR47","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/jdi.13960","volume":"14","author":"R Bouchi","year":"2023","unstructured":"Bouchi R, Kondo T, Ohta Y, et al. JDS Committee on Consensus Statement Development. A consensus statement from the Japan Diabetes Society: a proposed algorithm for pharmacotherapy in people with type 2 diabetes. J Diabetes Investig. 2023;14:151\u201364.","journal-title":"J Diabetes Investig"},{"key":"3157_CR48","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.116.003825","volume":"10","author":"LK George","year":"2017","unstructured":"George LK, Koshy SKG, Molnar MZ, et al. Heart failure increases the risk of adverse renal outcomes in patients with normal kidney function. Circ Heart Fail. 2017;10:e003825.","journal-title":"Circ Heart Fail"},{"key":"3157_CR49","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1001\/archinte.167.11.1130","volume":"167","author":"EF Elsayed","year":"2007","unstructured":"Elsayed EF, Tighiouart H, Griffith J, et al. Cardiovascular disease and subsequent kidney disease. Arch Intern Med. 2007;167:1130\u20136.","journal-title":"Arch Intern Med"},{"key":"3157_CR50","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.kint.2016.09.015","volume":"91","author":"K Tanaka","year":"2017","unstructured":"Tanaka K, Watanabe T, Takeuchi A, et al; CKD-JAC Investigators. Cardiovascular events and death in Japanese patients with chronic kidney disease. Kidney Int. 2017;91:227\u201334.","journal-title":"Kidney Int"},{"key":"3157_CR51","doi-asserted-by":"publisher","first-page":"sfae228","DOI":"10.1093\/ckj\/sfae228","volume":"17","author":"S Maruyama","year":"2024","unstructured":"Maruyama S, Tanaka T, Akiyama H, et al. Cardiovascular, renal and mortality risk by the KDIGO heatmap in Japan. Clin Kidney J. 2024;17:sfae228.","journal-title":"Clin Kidney J"},{"key":"3157_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108845","volume":"178","author":"M Ohsugi","year":"2021","unstructured":"Ohsugi M, Eiki J, Iglay K, et al. Comorbidities and complications in Japanese patients with type\u00a02 diabetes mellitus: retrospective analyses of J-DREAMS, an advanced electronic medical records database. Diabetes Res Clin Pract. 2021;178:108845.","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03157-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03157-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03157-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T09:03:05Z","timestamp":1747472585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03157-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3157"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03157-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ataru Igarashi has received lecture fees from Astellas Pharma Inc., Bayer Yakuhin, Ltd., Eli Lilly Japan K.K., Mitsubishi Tanabe Pharma Corporation, MSD Co., Ltd., Novartis Pharma K.K., and Ono Pharmaceutical Co., Ltd.; and belongs to the endowed department sponsored by Takeda Pharmaceutical Co., Ltd. Hisateru Tachimori belongs to the endowed department sponsored by Takeda Pharmaceutical Co., Ltd. Hiroyuki Takagi and Hiroki Akiyama are full-time employees of AstraZeneca K.K. Shun Kohsaka has received research funding from the Japan Society for the Promotion of Science and Pfizer, and has received consulting fees from Novartis and Bristol Myers Squibb, outside of the submitted work. Hiroaki Miyata has received research funding from AstraZeneca K.K. and Mitsubishi Tanabe Pharma Corporation. Keiko Maruyama-Sakurai, Yasumasa Segawa, and Naohiko Imai have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study is based on previously conducted studies and published literature and does not contain any new studies with human participants or animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}